CTNNB1 and neoplasm: In addition, we studied the relationship between PAQR3 and tumor microenvironment and drug IC50, and found that the expression level of PAQR3 was correlated with HSP90 inhibitor Tanespimycin (17-AAG), chemotherapy drugs Docetaxel, Nelarabine, Fludarabine, Zalcitabine (nucleoside analogue reverse transcriptase inhibitor (NRTI)), MEK inhibitor Mirdametinib (PD-0325901), Refametinib, Trametinib, Selumetinib, Wnt/beta-catenin Inhibitor XAV-939 and HER2 inhibitor Afatinib.